|
COVID-19 Vaccine Data
In Michigan, we have distributed 851,125 vaccines to state partners for administration. We have reported administering 642,111 first and second doses of vaccines for priority groups. This data is current data as of January 21, 2021.
|
|
How older adults and essential workers can be vaccinated
In addition to health care employees and staff and residents of long-term care facilities, older adults (ages 65+) and essential workers are now eligible to receive the vaccine, as supplies are available.
If supplies are unavailable through local health care providers, local health departments may be able to provide vaccines to some older adults and essential workers, although supplies are limited at this time. Individuals can check the website of their local health department to learn more about this option.
To identify the local health department and the services they may have available, visit Michigan.gov/COVIDvaccine and click How to Get a Vaccine.
Individuals who do not have access to the internet can call 888-535-6136 and press option “5” for help finding information about vaccination in your area and to schedule an appointment, if available.
|
|
Preliminary COVID-19 Vaccine Timeline
Everyone should begin to plan how they will receive the vaccine, but for many it will likely be several months before they are eligible. In the meantime, everyone is encouraged to start having conversations with their health care provider about getting vaccinated.
The timing of the start of a vaccination phase is dependent on the guidance from the Centers for Disease Control and Prevention (CDC) and the Advisory Committee on Immunization Practices (ACIP), supply of vaccine from the manufacturer, how vaccine is allocated from the federal level to Michigan, and capacity to administer vaccinations.
For more detailed information, review the COVID-19 Vaccine Prioritization Guidance.
 Based on information currently available, Michiganders can expect to become eligible to receive vaccine based on the Prelimary COVID-19 Vaccination Timeline.
|
|
|
The U.S. Food and Drug Administration (FDA) issued emergency use authorizations (EUA) for bamlanivimab (November 9, 2020) and casirivimab plus imdevimab (November 21, 2020). Both therapeutic products are available for the treatment of mild-to-moderate COVID-19 in non-hospitalized adult and pediatric patients (>12 years old and >40 kg) who are at high risk for progressing to severe COVID-19 and/or hospitalization.
While the safety and effectiveness of these investigational therapies appear promising, the data are still very limited. Clinical trials are ongoing to collect additional data on their safety and effectiveness.
To date, more than 2,000 Michiganders have received monoclonal antibodies in their course of treatment for COVID-19. A physician’s order is required, though it may vary from site to site as each hospital/system is running things a little differently. Some are infusing at their emergency department after consult with an emergency physician, while others are partnering with internal and/or external partners for delivery of the drug
 |
|
A Message from Dr. Khaldun and Dr. Fales
Read this message from Dr. Khaldun and Dr. Fales for additional information about monoclonal antibody therapies for providers, including locations where monoclonal antibody therapies are available to be administered.
|
|
|
|
|
